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ABSTRACT
Background
Reduced glomerular filtration rate (GFR) is associated with increased cardiovascular risk in
young and middle aged individuals. Associations with cardiovascular disease and mortality in
older people are less clearly established. We aimed to determine the predictive value of the
GFR for mortality and morbidity using data from the 5,804 participants randomized in the
Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
Methods and Findings
Glomerular filtration rate was estimated (eGFR) using the Modification of Diet in Renal Disease
equation and was categorized in the ranges ([20–40], [40–50], [50–60])   60 ml/min/1.73 m
2.
Baseline risk factors were analysed by category of eGFR, with and without adjustment for other
risk factors. The associations between baseline eGFR and morbidity and mortality outcomes,
accrued after an average of 3.2 y, were investigated using Cox proportional hazard models
adjusting for traditional risk factors. We tested for evidence of an interaction between the
benefit of statin treatment and baseline eGFR status. Age, low-density lipoprotein (LDL) and
high-density lipoprotein (HDL) cholesterol, C-reactive protein (CRP), body mass index, fasting
glucose, female sex, histories of hypertension and vascular disease were associated with eGFR (p
¼0.001 or less) after adjustment for other risk factors. Low eGFR was independently associated
with risk of all cause mortality, vascular mortality, and other noncancer mortality and with fatal
and nonfatal coronary and heart failure events (hazard ratios adjusted for CRP and other risk
factors (95% confidence intervals [CIs]) for eGFR , 40 ml/min/1.73m
2 relative to eGFR   60 ml/
min/1.73m
2 respectively 2.04 (1.48–2.80), 2.37 (1.53–3.67), 3.52 (1.78–6.96), 1.64 (1.18–2.27), 3.31
(2.03–5.41). There were no nominally statistically significant interactions (p , 0.05) between
randomized treatment allocation and eGFR for clinical outcomes, with the exception of the
outcome of coronary heart disease death or nonfatal myocardial infarction (p¼0.021), with the
interaction suggesting increased benefit of statin treatment in subjects with impaired GFRs.
Conclusions
We have established that, in an elderly population over the age of 70 y, impaired GFR is
associated with female sex, with presence of vascular disease, and with levels of other risk
factors that would be associated with increased risk of vascular disease. Further, impaired GFR is
independently associated with significant levels of increased risk of all cause mortality and fatal
vascular events and with composite fatal and nonfatal coronary and heart failure outcomes. Our
analyses of the benefits of statin treatment in relation to baseline GFR suggest that there is no
reason to exclude elderly patients with impaired renal function from treatment with a statin.
The Editors’ Summary of this article follows the references.
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Reduced glomerular ﬁltration rate (GFR) is associated with
increased cardiovascular risk in young and middle aged
individuals [1]. It is predictive of increased all-cause and
cardiovascular mortality in individuals with vascular disease
[2], greater severity of vascular disease [3], and worse outcome
including increased mortality in heart failure [4–6] and after
acute myocardial infarction [7,8]. Tools designed to assess
cardiovascular risk in middle-aged individuals, such as the
Framingham risk calculator, consistently underestimate event
rates in patients with reduced GFR [9].
The associations of reduced GFR with incident cardiovas-
cular disease and mortality in older people are less clearly
established. In healthy community-dwelling older people in
the US Cardiovascular Health Study, raised serum creatinine
and reduced estimated GFR had no signiﬁcant association
with cardiovascular events or total mortality [10]. In elderly
men in the British Regional Heart Study, where outcome was
restricted to mortality, the association between mild-to-
moderate renal insufﬁciency and outcome was explained to
a signiﬁcant extent by other risk factors [11].
We aimed to determine the predictive value of the GFR for
all-cause and vascular mortality and incident vascular events
in older people at risk of vascular disease using data from the
Prospective Study of Pravastatin in the Elderly at Risk
(PROSPER). This was a clinical trial of the HMG co-enzyme
A reductase inhibitor pravastatin versus placebo in elderly
men and women with a history of, or at risk for, vascular
disease [12–14].
Methods
The PROSPER study included 5,804 men and women
between the ages of 70 and 82 y, recruited in Scotland,
Ireland, and The Netherlands. The design, baseline character-
istics of the participants, and the primary study results have
been published elsewhere [12–14]. Selection criteria included
pre-existing vascular disease (coronary, cerebral, or periph-
eral) or increased risk of such disease because of smoking,
hypertension, or diabetes. Fasting baseline plasma total
cholesterol was in the range 4.0–9.0 mmol/l and triglyceride
concentrations were less than 6.0 mmol/l. Individuals with
baseline creatinine levels over 200 lmol/l were excluded.
Ethics committees of all trial centres approved the protocol,
and all participants provided written informed consent.
Participants were randomised to receive either pravastatin
40 mg or matching placebo, to be taken once daily.
Participants attended trial visits every 3 mo, with a mean
follow-up of 3.2 y. Lipoprotein proﬁles were measured at the
Centre for Disease Control–certiﬁed central lipoprotein
laboratory in Glasgow. Serum creatinine levels were meas-
ured at central laboratories, one in each of the three
participating countries. GFR was estimated using the Mod-
iﬁcation of Diet in Renal Disease equation [15,16]:
eGFR ¼ 1863Scrð 1:154Þ 3ageð 0:203Þ 30:742 ½if female ;
where Scr denotes serum creatinine level (mg/dl). It is
assumed that all participants were of Northern European
descent.
The primary outcome of the original trial was the
combined endpoint of death from CHD, nonfatal myocardial
infarction, and fatal or nonfatal stroke, assessed in the entire
cohort. All deaths and all cancers were recorded. Tertiary
endpoints included an assessment of transient ischemic
attacks. All clinical endpoints were adjudicated by an expert
study endpoints committee blinded to randomised study
medication and using predeﬁned criteria.
Outcomes studied in this report include death from all
causes, and deaths from vascular causes, cancer and deaths
from other noncancer noncardiovascular causes, the compo-
site outcome of coronary heart disease death or nonfatal
myocardial infarction, cerebrovascular events (fatal or non-
fatal stroke or transient ischaemic attack), and the composite
of death or hospitalization due to heart failure.
All study data were processed and analysed at the study
Data Centre in The Robertson Centre for Biostatistics,
University of Glasgow. Statistical analysis of baseline charac-
teristics was based on a comparison among subgroups based
on ranges of eGFR ([20–40], [40–50], [50–60]   60 ml/min/1.73
m
2), ﬁrst unadjusted and then adjusted for the potentially
confounding effects of study inclusion criteria (histories of
vascular disease, diabetes, hypertension, and current smoking
status, all categorized as yes/no) as well as age and gender.
Diabetes was deﬁned to be self-reported history, a fasting
blood glucose concentration of 7.0 mmol/l or greater, or a
blood glucose measurement of 11.1 mmol/l or greater when
fasting status was uncertain, or self-reported use of anti-
diabetic drugs (any oral hypoglycaemic agent or insulin).
Only 18 participants had eGFR , 30 ml/min/1.73 m
2, making
impracticable further subdivision at the bottom end of the
eGFR range. Continuous variables are summarized by means
and standard deviations and compared by one-way analysis of
variance or covariance as appropriate with the calculation of
a p-value for the general test of heterogeneity among the
eGFR categories. Categorical variables are summarized by
counts and percentages and compared using logistic regres-
sion analyses, with a general test of heterogeneity among the
categories of eGFR, with and without adjustment for the
confounding factors. To aid interpretation of the adjusted
analyses, adjusted expected values were estimated for the
continuous variables using the method of population
adjusted means [17]. A corresponding approach was used
for estimating expected proportions for the categorical
variables. The relationships between baseline eGFR and each
clinical outcome were assessed using Cox-proportional
hazards models with e-GFR subdivided by the categories
given above and treating the group with eGFR   60 ml/min/
1.73 m
2 as the referent. Evidence of a treatment by eGFR
interaction was investigated with eGFR as a continuous
variable to maximize statistical power. All analyses reported
were adjusted for the following baseline confounders:
country (Ireland, Netherlands, or Scotland); sex (male or
female); smoking (current or not current); age; histories (yes/
no) of each of hypertension, diabetes, and vascular diseases;
low-density lipoprotein cholesterol (LDL-C); high-density
lipoprotein cholesterol (HDL-C); systolic blood pressure
(SBP); diastolic blood pressure (DBP); body mass index
(BMI); fasting plasma glucose concentration. To explore the
inﬂuence of inﬂammation on the results, the analyses were
conducted with and without adjustment for C-reactive
protein (CRP). Validity of the proportional hazards assump-
tion was assessed by testing the signiﬁcance of interaction
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dependent covariate.
Results
Baseline eGFR data were available for 5,796 (99.9%) of the
5,804 randomised participants and this group forms the
population whose data were analysed. The numbers (percen-
tages) of participants in the prespeciﬁed categories of eGFR
were 349 (6.0%), 1,104 (19.0%), 1,641 (28.3%), 2,702 (46.6%)
in the categories (20–40), (40–50), (50–60), and  60 ml/min/
1.73 m
2, respectively.
Comparisons of baseline characteristics among the catego-
ries of eGFR are given in Table 1. In unadjusted analyses
there are statistically signiﬁcant associations between im-
paired renal function and older age, raised levels of low
density lipoprotein cholesterol, body mass index, fasting
plasma glucose and CRP, female sex and histories of hyper-
tension, vascular disease and current smoking. In analyses
adjusting for the skewing effect of study inclusion criteria
most of the associations remain highly statistically signiﬁcant
and qualitatively unchanged with the exception of high
density lipoprotein cholesterol (HDL-C), where there is now a
strong statistical association with low levels of HDL-C, and for
current smoking where, although the association is nominally
statistically signiﬁcant, the effect is attenuated.
Data on baseline cardiovascular medications are given in
Table 2. There was no difference among the eGFR categories
with respect to the use of ACE inhibitors, with or without
adjustment for baseline confounders. For beta blockers,
calcium channel blockers, nitrates, diuretics, and aspirin or
anticoagulants there was evidence of higher use in the group
with eGFR in the range (20–40) ml/min/1.73 m
2. With the
exception of diuretics, these differences were signiﬁcantly
attenuated after adjusting for baseline confounders. How-
ever, even in the adjusted analyses use of these medications
was numerically highest in the range (20–40) ml/min/1.73 m
2.
Table 3 contains details of event rates and estimated hazard
ratios relative to the category   60 ml/min/1.73 m
2 for the
other categories of eGFR. When data were analysed without
adjustment for levels of CRP, for all-cause mortality there was
evidence of a greater than 2-fold increase in risk in the group
with eGFR in the range (20–40) ml/min/1.73 m
2 and a 40%
increase in risk in the (40–50) ml/min/1.73 m
2 group in
comparison to the referent group. There was no association
with cancer mortality. However, there was a strong associa-
tion for vascular mortality mirroring the patterns seen for
death from all causes. There was also a signiﬁcant increase in
risk of deaths from other causes (noncardiovascular, non-
cancer) in the (20–40) ml/min/1.73 m
2 group. Although this
category of 106 deaths contained a small number (n ¼ 5) of
deaths due to renal failure, the most common causes were
pulmonary infection (n ¼ 33), chronic obstructive pulmonary
disease (n ¼17), septicaemia (n¼6), and other infections (n ¼
5). There was evidence of substantial increases in risk in the
(20–40) ml/min/1.73 m
2 and (40–50) ml/min/1.73 m
2 groups for
coronary death or nonfatal myocardial infarction and for
heart failure death or heart failure hospitalization. There was
no signiﬁcant association with the risk of stroke or transient
ischaemic attack. There was at most a modest attenuation of
the prognostic strength of eGFR after adjustment for levels of
CRP (Table 3).
During follow-up, a total of 64 participants experienced
serious adverse events classiﬁed as renal failure, 14 (4.0%), 20
(1.8%), 11 (0.7%), and 19 (0.7%) in the (20–40), (40–50), (50–
60), and   60 ml/min/1.73 m
2 groups respectively.
When tests for evidence of interaction between random-
ized treatment and eGFR in predicting each study outcome
were carried out, the only result that achieved statistical
signiﬁcance was for the outcome of coronary heart disease
death or nonfatal myocardial infarction (p ¼ 0.021). In this
case, there was a suggestion of greater beneﬁt from
pravastatin treatment relative to placebo in patients with a
greater degree of impairment of eGFR, with a strong
Table 1. Baseline Characteristics Split by Baseline eGFR Category and Overall
Variables eGFR Categories (ml/min/1.73 m
2) Mean (SD) [Geometric Mean for CRP] Total, n=5,796 pua pa
(20–40), n=349 (40–50), n=1,104 (50–60), n=1,641  60, n 2,702
Age (y) 77.1 (3.4) [76.6] 75.9 (3.4) [75.6] 75.3 (3.3) [75.0] 74.9 (3.2) [74.8] 75.3 (3.3) ,0.0001 ,0.0001
SBP (mmHg) 154.7 (22.5) [154.1] 154.9 (21.1) [154.8] 154.5 (22.0) [155.0] 154.6 (21.9) [155.2] 154.7 (21.8) 0.97 0.82
DBP (mmHg) 82.3 (10.3) [81.8] 83.6 (11.1) [82.9] 83.7 (11.5) [83.1] 84.0 (11.6) [83.5] 83.8 (11.5) 0.055 0.067
LDL-C (mmol/l) 4.0 (0.9) [3.8] 4.0 (0.8) [3.8] 3.8 (0.8) [3.7] 3.7 (0.8) [3.7] 3.8 (0.8) ,0.0001 ,0.0001
HDL-C (mmol/l) 1.26 (0.35) [1.17] 1.27 (0.36) [1.20] 1.27 (0.35) [1.23] 1.29 (0.36) [1.26] 1.28 (0.36) 0.36 ,0.0001
Body mass index 27.4 (4.1) [27.3] 27.4 (4.6) [27.2] 26.7 (4.1) [26.7] 26.6 (4.1) [26.7] 26.8 (4.2) ,0.0001 0.00021
Glucose (mmol/l) 5.5 (1.5) [5.5] 5.5 (1.3) [5.5] 5.6 (1.5) [5.6] 5.3 (1.4) [5.3] 5.4 (1.4) ,0.0001 ,0.0001
CRP (mg/l) 4.18 (2.94) [4.57] 3.35 (3.22) [3.71] 2.97 (3.16) [3.29] 2.94 (2.94) [3.25] 3.09 (3.06) ,0.0001 ,0.0001
Sex (male) 91 (26.1) [34.4] 363 (32.9) [42.0] 790 (48.1) [56.7] 1,555 (57.5) [65.4] 2,799 (48.3) ,0.0001 ,0.0001
History of hypertension 251 (71.9) [52.5] 773 (70.0) [49.2] 1,023 (62.3) [42.7] 1,538 (56.9) [39.6] 3,585 (61.9) ,0.0001 ,0.0001
Diabetes 41 (11.8) [9.3] 128 (11.7) [8.4] 192 (11.8) [7.8] 373 (13.9) [9.2] 734 (12.8) 0.11 0.32
Current smoker 60 (17.2) [14.1] 221 (20.0) [13.3] 407 (24.8) [13.5] 870 (32.2) [16.3] 1,558 (26.9) ,0.0001 0.022
History of vascular disease 190 (54.4) [54.1] 519 (47.0) [62.3] 752 (45.8) [66.1] 1,100 (40.7) [71.6] 2,561 (44.2) ,0.0001 ,0.0001
Mean (standard deviation [SD]) [geometric mean for CRP] are given for continuous variables and n (%) for categorical variables. p-Values are for unadjusted comparisons (pUA) and
adjusted comparisons (pA) among the categories. For each continuous variable, in each category, adjusted means are also given in square parentheses, adjusting for age, sex, and histories
of hypertension, diabetes, smoking, vascular disease, and baseline medications (excluding where relevant the variable being studied). For categorical variables corresponding adjusted
percentages are given.
Abbreviations: DBP, diastolic blood pressure; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; SBP, systolic blood pressure.
doi:10.1371/journal.pmed.1000016.t001
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GFR in Older Patientsassociation between eGFR and outcome in the placebo group
but not in the pravastatin group (Table 4).
There was no evidence of signiﬁcant departures from the
assumption of proportionality of hazards for any of the
outcomes.
Discussion
We have shown signiﬁcant independent associations of
reduced eGFR (below 50 ml/min/1.73 m
2) with all-cause
mortality, vascular deaths, coronary heart disease events
(coronary death or nonfatal myocardial infarction), and for
heart failure death or hospitalization, in an elderly popula-
tion with vascular disease or vascular disease risk factors.
There appeared to be a strong gradient of effect, with risks
greatest in those with eGFR in the range (20–40) ml/min/1.73
m
2, although signiﬁcant increases in the incidence of these
adverse events were also seen in the group with eGFR in the
range (40–50) ml/min/1.73 m
2. We found no evidence of
increased risk associated with eGFR in the range (50–60) ml/
min/1.73 m
2 in comparison to the reference group (eGFR  
60 ml/min/1.73 m
2) for any of the outcomes studied. Reduced
eGFR was not predictive of incident cerebrovascular events,
or as expected, with cancer deaths. We have shown that
presence of impaired renal function is independently
associated with older age, obesity, raised fasting glucose
levels, raised low-density lipoprotein cholesterol and reduced
high-density lipoprotein cholesterol, female gender, history
of vascular disease and hypertension. These relationships are
generally what would be expected from the literature. We did
not ﬁnd any association with diabetes, with if anything
slightly higher rates of diabetes in those with preserved eGFR.
Lower muscle mass can in some elderly individuals lead eGFR
to be higher than it otherwise would be. Since high hip
circumference as a proxy for higher muscle mass is
consistently shown to be protective for diabetes [18], then
lower muscle mass would increase diabetes risk. This may be
one possible explanation for our ﬁnding. Alternatively this
could be an artefact of the inclusion/exclusion criteria of the
study or a population selection effect in this elderly
population, linked to the decreased prevalence of males
and diabetics in those with eGFR , 60 ml/min/1.73 m
2. The
strong unadjusted association between smoking and high
eGFR was surprising. However, this association is almost
completely eliminated by adjustment for study-design con-
founders and is plausibly due to residual confounding.
Analyses of baseline cardiovascular medications revealed
no evidence that participants with impaired renal function
were less well treated. In middle-aged individuals with
vascular disease the eGFR is predictive of all-cause, coronary
heart disease and vascular mortality [1,2]. The predictive
value in elderly patients has been uncertain. Our results
contrast with those from lower-risk healthy community
dwelling older individuals in whom eGFR appeared to have
little predictive value [10,19]. Our data are from a high-risk
elderly population, and in this context eGFR appears to have
strong predictive value. In our high risk population with
availability of carefully adjudicated nonfatal outcomes as well
as fatal outcomes we were able to identify stronger
associations at lower levels of eGFR than was possible in the
analyses of data from the British Regional Heart Study [11]. In
a study of even older patients from the Leiden 85-Plus Study
[20] no association was found between baseline systolic blood
pressure and impaired GFR. However, there was evidence in
that study of statistically signiﬁcantly lower eGFR levels at
lower levels of diastolic blood pressure. In our study we found
no association with systolic blood pressure and a nonstatisti-
cally signiﬁcant trend suggesting slightly lower diastolic blood
pressures in individuals with lower levels of eGFR. The lack of
any statistically signiﬁcant association between eGFR and
cerebrovascular event risk is interesting. It is true that
cerebrovascular events were less common than coronary
events with lower associated power to detect any association.
A large cross-sectional study of older adults has found an
association of low GFR with prior stroke [21], however this
has not been borne out in prospective cohorts. In the
Rotterdam study Bos et al. [22], showed no signiﬁcant
association of low GFR with incident ischaemic stroke. Two
other studies have also reported no association of low GFR
with stroke [23,24]. It is noteworthy, in our study, that there
was a lack of association between systolic blood pressure and
eGFR.
Our results were not materially affected by adjustment for
a measure of inﬂammation (CRP). There are a number of
potential mechanisms by which low GFR may be associated
with increased risk of adverse outcomes. Low GFR is
associated with vascular risk factors including a history of
hypertension and an unfavourable lipid proﬁle, and an
increased burden of underlying coronary atheroma [3]. This
Table 2. Common Baseline Cardiovascular Medications Split by Baseline eGFR Category and Overall
Variables eGFR Categories (ml/min/1.73 m
2) [Adjusted Percentages] Total, n=5,796 pua pa
(20–40), n=349, (40–50), n=1,104 (50–60), n=1,641  60, n 2,702
Beta blockers 119 (34.1) [21.1] 310 (28.1) [16.8] 426 (26.0) [16.3] 644 (23.8) [16.4] 1,499 (25.9) 0.00011 0.10
Calcium channel blockers 109 (31.2) [23.4] 305 (27.6) [21.6] 443 (27.0) [21.8] 600 (22.2) [18.9] 1,457 (25.1) ,0.0001 0.034
Nitrates 94 (26.9) [18.5] 232 (21.0) [13.9] 337 (20.5) [13.0] 428 (15.8) [9.7] 1,091 (18.8) ,0.0001 0.012
ACE inhibitors 66 (18.9) [11.7] 192 (17.4) [11.0] 253 (15.4) [10.5] 437 (16.2) [12.2] 948 (16.4) 0.30 0.29
Diuretics 212 (60.7) [40.9] 586 (53.1) [34.2] 666 (40.6) [26.2] 889 (32.9) [22.2] 2,353 (40.6) ,0.0001 ,0.0001
Aspirin or anticoagulants 155 (44.4) [37.1] 436 (39.5) [35.3] 640 (39.0) [34.9] 967 (35.8) [33.7] 2,198 (37.9) 0.0038 0.68
n (%) are given with p-values are for unadjusted comparisons (pUA) and adjusted comparisons (pA) among the categories. For each continuous variable, in each category adjusted
percentages are given in square parentheses, adjusting for age, sex, and histories of hypertension, diabetes, smoking, vascular disease, and baseline medications (excluding where relevant
the variable being studied).
doi:10.1371/journal.pmed.1000016.t002
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GFR in Older Patientsis likely to increase the risk of myocardial infarction and of
death in those who have a coronary event. Hence, low eGFR
could merely be a marker for cardiovascular risk rather than
being causally implicated. However, in some situations low
GFR may be a direct cause of vascular events or death. In
heart failure, kidney disease is associated with impaired intra-
cardiac conduction and progressive deterioration of diastolic
function [6]. There are also associations with left-ventricular
hypertrophy [7]. Further, inﬂammation, endothelial dysfunc-
tion, hypercoagulability, and raised homocysteine may play a
role [11].
We identiﬁed a nominally statistically signiﬁcant interac-
tion between treatment with pravastatin and eGFR level for
the outcome of coronary heart disease death or nonfatal
myocardial infarction. The results are compatible with the
increased risk associated with impaired renal function being
eliminated in the group treated with pravastatin. We believe
that this result should be treated cautiously because of the
borderline level of signiﬁcance, the fact that a number of tests
of interaction were carried out, with one signiﬁcant result,
and because the result suggests a greater beneﬁt of statin
treatment in participants with the greatest degree of renal
impairment, arguably the opposite to what might be
expected. We also note that in the pooled analyses of earlier
trials with pravastatin, admittedly in a younger population,
such an interaction was not detected [25]. At the very least,
these results suggest that patients with signiﬁcantly impaired
renal function beneﬁt at least as much from statin treatment
as do those with preserved renal function. Ongoing studies of
the beneﬁts of statin treatment in patients with chronic
kidney disease are currently underway to investigate this
patient population further [26].
There are a number of limitations to our study. We were
restricted in our measures of renal function to eGFR.
Cystatin-C may be a better predictor of outcomes, including
in elderly patients [10,18]. We have no measure of albumi-
nuria. The population that we studied was selected for a
clinical trial with speciﬁc inclusion and exclusion criteria,
and may not be fully representative of older people with
vascular disease or vascular risk factors. There is the
possibility that, despite careful adjustment, associations or
the lack thereof between eGFR and baseline factors could be
biased. Strengths of our study include assiduous follow-up
and rigorous methods of classiﬁcation of deaths and nonfatal
clinical events. This high-risk population gave a large number
of deaths and nonfatal vascular events, and therefore gives
good statistical power to detect associations for a wide range
of levels of eGFR.
In conclusion, we have established that impaired GFR, in an
elderly population over the age of 70 y, is independently
associated with signiﬁcant levels of increased risk of all cause
mortality and of fatal and nonfatal coronary and heart failure
events. Our analyses of the beneﬁts of statin treatment in
relation to baseline renal function suggest that there is no
reason to exclude elderly patients with impaired renal
function from treatment with a statin.
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Editors’ Summary
Background. Cardiovascular disease (CVD)—disease that affects the
heart and/or the blood vessels—is a common cause of death in
developed countries. In the USA, for example, the single leading cause of
death is coronary heart disease, a CVD in which narrowing of the heart’s
blood vessels slows or stops the blood supply to the heart and
eventually causes a heart attack. Other types of CVD include stroke (in
which narrowing of the blood vessels interrupts the brain’s blood supply)
and heart failure (a condition in which the heart can no longer pump
enough blood to the rest of the body). Many factors increase the risk of
developing CVD, including high blood pressure (hypertension), high
blood cholesterol, having diabetes, smoking, and being overweight.
Tools such as the ‘‘Framingham risk calculator’’ assess an individual’s
overall CVD risk by taking these and other risk factors into account. CVD
risk can be minimized by taking drugs to reduce blood pressure or
cholesterol levels (for example, pravastatin) and by making lifestyle
changes.
Why Was This Study Done? Another potential risk factor for CVD is
impaired kidney (renal) function. In healthy people, the kidneys filter
waste products and excess fluid out of the blood. A reduced ‘‘estimated
glomerular filtration rate’’ (eGFR), which indicates impaired renal
function, is associated with increased CVD in young and middle-aged
people and increased all-cause and cardiovascular death in people who
have vascular disease. But is reduced eGFR also associated with CVD and
death in older people? If it is, it would be worth encouraging elderly
people with reduced eGFR to avoid other CVD risk factors. In this study,
the researchers determine the predictive value of eGFR for all-cause and
vascular mortality (deaths caused by CVD) and for incident vascular
events (a first heart attack, stroke, or heart failure) using data from the
Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). This
clinical trial examined pravastatin’s effects on CVD development among
70–82 year olds with pre-existing vascular disease or an increased risk of
CVD because of smoking, hypertension, or diabetes.
What Did the Researchers Do and Find? The trial participants were
divided into four groups based on their eGFR at the start of the study.
The researchers then investigated the association between baseline CVD
risk factors and baseline eGFR and between baseline eGFR and vascular
events and deaths that occurred during the 3-year study. Several
established CVD risk factors were associated with a reduced eGFR after
allowing for other risk factors. In addition, people with a low eGFR
(between 20 and 40 units) were twice as likely to die from any cause as
people with an eGFR above 60 units (the normal eGFR for a young
person is 100 units; eGFR decreases with age) and more than three times
as likely to have nonfatal coronary heart disease or heart failure. A low
eGFR also increased the risk of vascular mortality, other noncancer
deaths, and fatal coronary heart disease and heart failure. Finally,
pravastatin treatment reduced coronary heart disease deaths and
nonfatal heart attacks most effectively among participants with the
greatest degree of eGFR impairment.
What Do These Findings Mean? These findings suggest that, in elderly
people, impaired renal function is associated with levels of established
CVD risk factors that increase the risk of vascular disease. They also
suggest that impaired kidney function increases the risk of all-cause
mortality, fatal vascular events, and fatal and nonfatal coronary heat
disease and heart failure. Because the study participants were carefully
chosen for inclusion in PROSPER, these findings may not be general-
izable to all elderly people with vascular disease or vascular disease risk
factors. Nevertheless, increased efforts should probably be made to
encourage elderly people with reduced eGFR and other vascular risk
factors to make lifestyle changes to reduce their overall CVD risk. Finally,
although the effect of statins in elderly patients with renal dysfunction
needs to be examined further, these findings suggest that this group of
patients should benefit at least as much from statins as elderly patients
with healthy kidneys.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
1000016.
  The MedlinePlus Encyclopedia has pages on coronary heart disease,
stroke, and heart failure (in English and Spanish)
  MedlinePlus provides links to many other sources of information on
heart disease, vascular disease, and stroke (in English and Spanish)
  The US National Institute of Diabetes and Digestive and Kidney
Diseases provides information on how the kidneys work and what can
go wrong with them, including a list of links to further information
about kidney disease
  The American Heart Association provides information on all aspects of
cardiovascular disease for patients, caregivers, and professionals (in
several languages)
  More information about PROSPER is available on the Web site of the
Vascular Biochemistry Department of the University of Glasgow
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